Five-year outcomes in living donor kidney transplants with a positive crossmatch

American Journal of Transplantation

Volumn 13, Issue 1, 2013, Pages 76-85

  Bentall, A ^a,b   Cornell, L D ^a   Gloor, J M ^a   Park, W D ^a   Gandhi, M J ^a   Winters, J L ^a   Chedid, M F ^a   Dean, P G ^a   Stegall, M D ^a  

^a MAYO CLINIC   (United States)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Antibody mediated rejection; donor specific antibodies; HLA sensitized patients; Long term outcomes; positive crossmatch kidney transplant

Indexed keywords

HLA ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; CAPILLARITIS; CONTROLLED STUDY; DESENSITIZATION; FEMALE; FOLLOW UP; GLOMERULITIS; GLOMERULOPATHY; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA;

ADULT; CASE-CONTROL STUDIES; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84871722009     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04291.x     Document Type: Article

References (23)

1. Piazza A, Poggi E, Borrelli L, et al.. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106-1112.
2. Lachmann N, Terasaki PI, Budde K, et al.. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
3. Jordan SC, Vo A, Bunnapradist S, et al.. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631-636.
4. Montgomery RA ZA, Racusen LC, Leffell MS, et al.. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
5. Gloor JM, DeGoey SR, Pineda AA, et al.. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-1023.
6. Glotz D, Antoine C, Julia P, et al.. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758-760.
7. Gentry SE, Montgomery RA, Segev DL,. Kidney paired donation: Fundamentals, limitations, and expansions. Am J Kidney Dis 2011; 57: 144-151.
8. Ashlagi I, Gilchrist DS, Roth AE, Rees MA,. Nonsimultaneous chains and dominos in kidney- paired donation-revisited. Am J Transplant 2011; 11: 984-994.
9. Bingaman AW, Bray RA, Gebel HM, Newell KA,. Paired kidney donation: A (virtual) balancing act. Am J Transplant 2011; 11: 194-195.
10. Doxiadis, II, Claas FH,. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both. Curr Opin Organ Transplant 2009; 14: 410-413.
11. Montgomery RA, Lonze BE, King KE, et al.. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
12. Gloor JM, Cosio FG, Rea DJ, et al.. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847.
13. Racusen LC, Solez K, Colvin RB, et al.. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
14. Solez K, Colvin RB, Racusen LC, et al.. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
15. Rosenbaum PR,. Optimal matching for observational studies. J Am Stat Assoc 1989; 84: 1024-1032.
16. Amer H, Fidler ME, Myslak M, et al.. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007; 7: 2748-2756.
17. Haririan A, Nogueira J, Kukuruga D, et al.. Positive cross-match living donor kidney transplantation: Longer term outcomes. Am J Transplant 2009; 9: 536-542.
18. Lefaucheur C, Loupy A, Hill GS, et al.. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
19. Higgins R, Lowe D, Hathaway M, et al.. Human leukocyte antigen antibody-incompatible renal transplantation: Excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92: 900-906.
20. Haas M, Montgomery RA, Segev DL, et al.. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-585.
21. Loupy A, Suberbielle-Boissel C, Hill GS, et al.. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
22. Lerut E, Naesens M, Kuypers DR, Vanrenterghem Y, Van Damme B,. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007; 83: 1416-1422.
23. Montgomery RA,. Living donor exchange programs: Theory and practice. Br Med Bull 2011; 98: 21-30.